港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

恒瑞医药

71.100

-0.500-0.70%

成交量：267.09万

成交额：1.90亿

市值：4,718.91亿

市盈率：65.01

高：72.050

开：71.600

低：70.500

收：71.600

52周最高：95.200

52周最低：52.500

股本：66.37亿

香港流通股本：2.58亿

量比：0.69

换手率：1.04%

股息：- -

股息率：- -

每股收益(LYR):1.094

净资产收益率：14.34%

总资产收益率：8.37%

市净率：7.25

市盈率(LYR):65.01

市销率: 13.93

数据加载中...

总览公司新闻资讯公告

科创板重任在肩未来可期

金融投资报

独家专访恒瑞医药张连山：在慢病管理上的在研产品数量已超肿瘤药，恒瑞转型的决心是极大的｜上海药圈新拐点

恒瑞医药：富马酸泰吉利定注射液获临床试验批准

南方财经网

恒瑞医药(600276.SH)：HRS-4642注射液等多款药物获得临床试验批准

智通AH统计|11月17日

AD创新机制药物，深度相关的3家公司！

Ofweek光电信息网

智通港股空仓持单统计|11月14日

恒瑞医药(01276)：2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股

【券商聚焦】中金公司：国产创新药正从此前多年的“跟随式创新” 逐渐走出一批“后来居上”的优质管线

康惠股份追讨2.66亿元业绩补偿款，海思科1类新药获批临床，恒瑞医药二代AR抑制剂新进展，智云健康与京东健康签订服务合作协议

奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？

重磅！恒瑞医药口服小分子GLP-1RA（HRS-7535）糖尿病肾病最新研究亮相ASN 2025

管窥2025年处于全球研发中后期的国产创新药全景

CPHI制药在线

恒瑞医药SHR-3045注射液启动II期临床适应症为类风湿关节炎

恒瑞医药(600276.SH)获得瑞维鲁胺片药物临床试验批准通知书

每日卖空追踪 | 恒瑞医药 11月13日卖空量成交69.42万股，卖空比例为10.08%

智通AH统计|11月13日

医药行业收入与利润端现边际改善！创新药成为新的增长极

对话恒瑞医药张连山：不止于BD，驶向“造船出海”

中国医药创新促...

恒瑞医药张连山：中国真正的国际性医药企业，需在15年内将本土创新产品销往全球

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/01276/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":71.1,"timestamp":1763366895002,"preClose":71.6,"halted":0,"volume":2670935,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.0936783262453251,"marketStatus":"未开盘","change":-0.5,"latestTime":"11-17 16:08:15","open":71.6,"high":72.05,"low":70.5,"amount":189769648,"amplitude":0.021648,"askPrice":71.1,"askSize":2200,"bidPrice":70.85,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.2688943435364362,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":71.6,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.6906511434511522,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":61.8,"timestamp":1763362800000,"preClose":62.9,"halted":0,"volume":31538400,"delay":0,"premium":"+5.19"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.37%","roe":"14.34%","lyrEps":1.093678,"volumeRatio":0.6906511434511522,"shares":6637000000,"dividePrice":0,"high":72.05,"amplitude":0.021648,"preClose":71.6,"low":70.5,"week52Low":52.5,"pbRate":"7.25","psRate":"13.93","week52High":95.2,"institutionHeld":0,"latestPrice":71.1,"committee":-0.375,"eps":1.0936783262453251,"divideRate":0,"volume":2670935,"delay":0,"ttmEps":1.2688943435364362,"open":71.6,"prevYearClose":44.05,"prevWeekClose":71.6,"prevMonthClose":75.2,"prevQuarterClose":88.8,"fiveDayClose":71.2,"twentyDayClose":78.55,"sixtyDayClose":78.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5714,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1760716800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-11-14","current":56.046592,"percent":0.385246,"low":50.027905,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"high":65.582363,"avg":57.773326,"sd":4.626144,"marketCap":457058673340.29},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29}],"updateTime":1763410594016},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584625677","title":"科创板重任在肩未来可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625677","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625677?lang=zh_cn&edition=fundamental","pubTime":"2025-11-18 00:00","pubTimestamp":1763395200,"startTime":"0","endTime":"0","summary":"自2019年设立以来，科创板便突破传统盈利门槛，允许未盈利企业、红筹企业及特殊股权架构企业上市，开辟科创企业专属融资通道。以生物医药产业为例，科创板目前已集聚115家生物医药企业，涵盖重大疾病诊断、治疗、康复等领域，使科创板跻身全球第三大生物医药上市地，助力我国建设生物医药创新高地。科创板上市公司的经营是国际化的。当前，全球科技创新进入密集活跃期，中国资本市场的开放步伐也在持续加快。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117235158976f2e70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117235158976f2e70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","06978","BK1161","LU2543165471.USD","LU0359202008.SGD","BK1191","BK1574","LU0359201885.HKD","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2584677648","title":"独家专访恒瑞医药张连山：在慢病管理上的在研产品数量已超肿瘤药，恒瑞转型的决心是极大的｜上海药圈新拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2584677648","media":"科Way","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584677648?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 18:08","pubTimestamp":1763374109,"startTime":"0","endTime":"0","summary":"四年前，市场对A股“药茅”恒瑞医药的未来曾一度产生分歧；四年后的今天，公司的发展轨迹已给出清晰回应。值得注意的是，就在今年10月末，恒瑞医药位于张江总部经济园区的上海创新研发中心正式启用，成为上海与国内创新龙头企业双向奔赴的又一重要成果，也标志着公司全球化战略迈出坚实一步。近日，第一财经“上海药圈新拐点”系列独家专访了恒瑞医药执行副总裁、全球研发负责人张连山。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117182130a6ff254b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117182130a6ff254b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201885.HKD","LU1023057109.AUD","LU0359202008.SGD","01276","LU0359201612.USD","LU2543165471.USD"],"gpt_icon":0},{"id":"2584648444","title":"恒瑞医药：富马酸泰吉利定注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584648444","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584648444?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:25","pubTimestamp":1763367933,"startTime":"0","endTime":"0","summary":"南财智讯11月17日电，恒瑞医药公告，富马酸泰吉利定注射液收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意该药品开展用于重症监护患者机械通气时的镇痛的临床试验。富马酸泰吉利定注射液是μ阿片受体（MOR）偏向性小分子激动剂，截至目前相关项目累计研发投入约19,999万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511173566278071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU0359201885.HKD","01276","BK1191","LU2543165471.USD","LU1023057109.AUD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2584481376","title":"恒瑞医药(600276.SH)：HRS-4642注射液等多款药物获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584481376","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584481376?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:17","pubTimestamp":1763367456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于HRS-4642注射液、 SHR-1701 注射液、SHR-7367 注射液、SHR-8068 注射液、阿得贝利单抗注射液、贝伐珠单抗注射液、注射用SHR-A2102、苹果酸法米替尼胶囊和羟乙磺酸达尔西利片的《药物临床试验批准通知书》，将于近期开展临床试验。具体为：一项HRS-4642联合抗肿瘤药物在实体瘤受试者中的安全性、耐受性及有效性的ⅠB/Ⅱ期研究方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","LU1997244956.HKD","LU2097828474.EUR","LU2148510915.USD","BK1191","LU0359201885.HKD","LU1820825898.SGD","BK0196","BK0183","LU2580892789.USD","LU2495084118.USD","LU2328871848.SGD","LU2289578879.USD","LU1146622755.USD","LU1969619763.USD","LU0359201612.USD","LU0405327148.USD","LU2097828805.USD","LU0405327494.USD","LU1580142542.USD","LU1328615791.USD","600276","LU0359202008.SGD","LU1997245094.SGD","BK0028","LU2580892862.HKD","LU1997245177.USD","BK0188","01276","BK0012","BK0060","LU1781817850.SGD","LU2097828631.EUR","LU2488822045.USD","BK0239","LU1655091616.SGD","LU1255011170.USD","LU1064130708.USD","LU2097828714.EUR","LU2543165471.USD","LU2097828557.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2584485956","title":"智通AH统计|11月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=2584485956","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584485956?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:15","pubTimestamp":1763367305,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止11月17日收盘，东北电气、弘业期货、中石化油服分列AH溢价率前三位，溢价率分别为815.25%、277.62%、276.83%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-7.20%、-0.80%、4.11%。其中中伟新材、山东墨龙、浙江世宝的偏离值位居前三，分别为77.12%、35.17%、33.73%；另外，东北电气、赣锋锂业、安德利果汁的偏离值位居后三，分别为-22.71%、-21.06%、-18.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0106959298.USD","LU2097828631.EUR","02359","LU0244354667.USD","SG9999012710.SGD","80883","159982","02465","00300","01349","00568","03968","00670","LU1242518857.USD","00895","BK1184","00187","00042","03606","LU2476274720.SGD","02338","03678","01033","LU0348816934.USD","01276","03750","06031","01055","02899","02883","399300","LU0516422952.EUR","LU0164865239.USD","BK1144","01375","02218","LU0307460666.USD","06869","00883","LU0531971595.HKD","01812","01108","01988","01057","03143","02628","01138"],"gpt_icon":1},{"id":"2584567767","title":"AD创新机制药物，深度相关的3家公司！","url":"https://stock-news.laohu8.com/highlight/detail?id=2584567767","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584567767?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 15:03","pubTimestamp":1763362980,"startTime":"0","endTime":"0","summary":"核心1标志物用于AD的诊断，核心2标志物用于AD的分期。家族性AD常见于65岁以下人群，主要表现为早发性AD的形式。适用于轻度至中度AD患者，此类患者大脑中的乙酰胆碱水平降低导致认知功能受损。目前管线已经进入临床II期阶段，考虑到AD市场空间巨大，当前治疗药物短缺，随着临床研究推进，管线有望较大幅度提升公司估值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117151559a6feb67d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117151559a6feb67d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU1023057109.AUD","01276","LU0359202008.SGD","LU0359201885.HKD","LU2543165471.USD","LU0359201612.USD"],"gpt_icon":0},{"id":"2583572655","title":"智通港股空仓持单统计|11月14日","url":"https://stock-news.laohu8.com/highlight/detail?id=2583572655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583572655?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 18:30","pubTimestamp":1763116204,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止11月7日，未平仓空单比位列前三位为中兴通讯、万科企业、中远海控，空仓比分别为17.05%、16.80%、16.12%。未平仓空单比（绝对值）较上一次增加最多为国泰君安国际、天立国际控股、东方电气，分别增加3.09%、2.94%、1.77%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PAImain","02318","BK1509","LU0266512473.USD","01276","01133","02899","601318","01880","BK1612","02202","02359","00874","06680","BK1116","01773","LU0163747925.USD","01357","06821","HPAD.SI","LU2153592121.USD","BK1610","00763","03145","LU0791590937.USD","02488","PNGAY","02338","LU1720050803.USD","LU0359201885.HKD","LU1769817096.USD","01072","LU1769817179.HKD","06865","01788","BK1171","02432","06869","000002","01919","LU0762540952.USD","LU1282649810.SGD","00017","LU0648948544.HKD","LU1831875114.USD","03800","LU1235295612.USD","82318"],"gpt_icon":1},{"id":"2583571976","title":"恒瑞医药(01276)：2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583571976","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583571976?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 17:39","pubTimestamp":1763113177,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，截至本公告披露日，公司2022年员工持股计划第三个锁定期实际解锁股份共计283.03万股(占目前公司总股本的0.04%)。截至2025年11月14日，165.68万股非交易过户至员工持股计划份额持有人，117.35万股通过集中竞价交易方式出售。公司2022年员工持股计划管理委员会后续将根据本次员工持股计划的相关约定进行相应财产分配工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1580142542.USD","LU2580892789.USD","LU2097828714.EUR","LU2543165471.USD","LU1997244956.HKD","BK0183","LU1146622755.USD","LU2097828805.USD","LU0405327148.USD","LU2328871848.SGD","BK0060","LU1655091616.SGD","LU2097828474.EUR","LU1781817850.SGD","BK0012","LU2488822045.USD","LU1997245177.USD","LU1023057109.AUD","BK0188","LU1255011170.USD","LU0359201885.HKD","01276","LU2495084118.USD","LU2148510915.USD","BK1191","600276","LU1064131003.USD","LU1969619763.USD","LU2097828631.EUR","LU1064130708.USD","LU1820825898.SGD","LU2289578879.USD","LU1997245094.SGD","LU0405327494.USD","LU2097828557.USD","BK0196","BK0239","LU0359201612.USD","BK0028","LU2580892862.HKD","LU1328615791.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2583541546","title":"【券商聚焦】中金公司：国产创新药正从此前多年的“跟随式创新” 逐渐走出一批“后来居上”的优质管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2583541546","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583541546?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 09:04","pubTimestamp":1763082272,"startTime":"0","endTime":"0","summary":"我们认为国产创新药正从此前多年的“跟随式创新”中，通过沉淀积累从量变转为质变，逐渐走出一批“后来居上”、乃至“同类最佳”、“全球首创”的优质管线。近年国家医保基金结余缩窄，收支状况承压，导致创新药商业化与获批上市存在一定的节奏错位。我们认为，“十四五”期间系列政策的发布，从多个维度建立起围绕器械领域创新的配套机制，在具体环节提升监管效率，鼓励并助推高端医疗器械产业创新加速落地。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969628","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","IE00B5MMRT66.SGD","BK1147","06990","09926","LU2778985437.USD","01276","LU0307460666.USD","02268","01801","LU2125910500.SGD","LU1770034418.SGD","601995","LU0502904849.HKD","06978","BK1574","LU2097828474.EUR","LU0348784397.USD","LU1969619763.USD","159992","LU1046422090.SGD","SG9999014674.SGD","LU0348766576.USD","LU0359201885.HKD","LU0708995583.HKD","06160","02359","LU2476274720.SGD","LU1794554557.SGD","BK1588","LU0359201612.USD","IE00BPRC5H50.USD","03908","LU2097828714.EUR","LU2242644610.SGD","HK0000165453.HKD","LU0561508036.HKD","LU0417516738.SGD","BK1583","LU0348767384.USD","LU2097828805.USD","LU0588546209.SGD","LU0348735423.USD","BK1516","LU1580142542.USD","LU0348827113.USD","LU2399975544.HKD","BK1191","LU0320764599.SGD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2583423519","title":"康惠股份追讨2.66亿元业绩补偿款，海思科1类新药获批临床，恒瑞医药二代AR抑制剂新进展，智云健康与京东健康签订服务合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2583423519","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583423519?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 23:03","pubTimestamp":1763046211,"startTime":"0","endTime":"0","summary":"长春高新：公司子公司长春金赛药业有限责任公司收到美国食品药品监督管理局书面通知，金赛药业注射用GenSci143临床试验申请获得批准。康惠股份：近日公司向咸阳仲裁委员会申请仲裁，要求来新胜支付剩余业绩补偿款2.66亿元。智云健康：公司近日与京东健康股份有限公司订立服务合作协议，旨在拓宽莉芙敏片及其他P2M管线产品的线上销售与服务渠道，为患者提供更便捷的购药体验与专业的全周期健康管理服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114000124a49f6def&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114000124a49f6def&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1571","01276","LU0359201885.HKD","LU0051755006.USD","86618","BK1589","SGXZ62798434.SGD","BK1197","BK1247","09955","LU0359202008.SGD","06618","LU0359201612.USD","BK1583","LU0456827905.SGD","LU1023057109.AUD","BK1591","BK1191","BK1617","SGXZ86797644.SGD","BK1615","LU2543165471.USD","BK1142"],"gpt_icon":0},{"id":"2583562646","title":"奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562646","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562646?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 20:07","pubTimestamp":1763035620,"startTime":"0","endTime":"0","summary":"　　11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？”　　杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。他表示，生物医药企业要在全球产生价值，必须先在中国市场形成价值基础，而国家在政策端的持续支持至关重要。　　现场讨论认为，随着创新能力提升、政策不断完善，中国医药产业未来有望孕育世界级的一流企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688293","BK0239","BK0216","LU1064131003.USD","LU1580142542.USD","LU0405327494.USD","LU1997245094.SGD","688606","BK0196","LU1820825898.SGD","LU1064130708.USD","LU1255011170.USD","BK0188","LU1969619763.USD","LU2289578879.USD","BK0183","01276","LU2097828474.EUR","LU0359201885.HKD","LU2488822045.USD","LU2580892789.USD","LU1997244956.HKD","LU2097828631.EUR","BK0028","600276","BK0012","LU0359202008.SGD","LU2097828805.USD","LU1997245177.USD","LU0405327148.USD","LU0359201612.USD","LU1328615791.USD","LU2097828714.EUR","LU2148510915.USD","LU1655091616.SGD","LU2580892862.HKD","LU1023057109.AUD","BK1191","LU2097828557.USD","LU1146622755.USD","LU2495084118.USD","LU1781817850.SGD","LU2328871848.SGD","BK0060","LU2543165471.USD"],"gpt_icon":0},{"id":"2583519429","title":"重磅！恒瑞医药口服小分子GLP-1RA（HRS-7535）糖尿病肾病最新研究亮相ASN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583519429","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583519429?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 18:10","pubTimestamp":1763028625,"startTime":"0","endTime":"0","summary":"在此背景下，恒瑞医药自主研发的口服小分子GLP-1RA HRS-7535的Ⅱ期研究成果[1]，于11月5日至9日在美国休斯顿举行的2025年美国肾脏学会年会“最新突破性研究口头报告”专场重磅发布。HRS-7535是全球首个在DKD人群中完成概念性验证的口服小分子GLP-1RA，有望为DKD患者带来全新治疗选择。作为全球首个在DKD人群中完成概念性验证的口服小分子GLP-1RA，HRS-7535 Ⅱ期研究证实了其在DKD治疗中的潜在价值，同时为国内DKD精准治疗提供了重要的本土化循证依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113184748a6f6d38d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113184748a6f6d38d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","BK1191","LU0359201612.USD","LU1023057109.AUD","01276","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2583594406","title":"管窥2025年处于全球研发中后期的国产创新药全景","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594406","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583594406?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 18:03","pubTimestamp":1763028209,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线2025年11月，一批国产创新药已迈入全球研发中后期，这不仅是中国医药产业从“仿创结合”向“全球新”进阶的实证，更折射出国内药企在全球创新赛道的布局逻辑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191040a49ee2a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191040a49ee2a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU0502904849.HKD","BK1161","LU1969619763.USD","BK1589","06855","LU0455707207.USD","BK1583","LU2488822045.USD","LU2097828714.EUR","LU2097828557.USD","06978","BK1574","LU2097828631.EUR","HK0000165453.HKD","01801","LU2097828474.EUR","01276","LU2328871848.SGD","09995","02162","LU2242644610.SGD"],"gpt_icon":0},{"id":"2583447519","title":"恒瑞医药SHR-3045注射液启动II期临床 适应症为类风湿关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2583447519","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583447519?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 18:03","pubTimestamp":1763028180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，广东恒瑞医药有限公司/上海恒瑞医药有限公司的评价SHR-3045注射液在中至重度活动性类风湿关节炎患者中有效性和安全性的随机、双盲、安慰剂对照的IIa期研究已启动。该药物剂型为注射液，用法用量按方案规定使用。SHR-3045注射液为生物制品，适应症为类风湿关节炎。类风湿关节炎是一种自身免疫性疾病，主要症状为关节疼痛、肿胀、僵硬，尤其在早晨或休息后加重。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113185539a49edb79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113185539a49edb79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","01276","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD","BK1191","LU0359202008.SGD"],"gpt_icon":0},{"id":"2583557855","title":"恒瑞医药(600276.SH)获得瑞维鲁胺片药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2583557855","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583557855?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 16:51","pubTimestamp":1763023886,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到国家药品监督管理局核准签发关于瑞维鲁胺片的《药物临床试验批准通知书》，将于近期开展临床试验。瑞维鲁胺片是第二代AR抑制剂，相较于第一代AR抑制剂，具有更强的AR抑制作用，且无激动作用。公司瑞维鲁胺片已于2022年获批上市，用于治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU1146622755.USD","BK0188","LU0405327494.USD","LU1064131003.USD","LU1064130708.USD","LU2580892789.USD","LU1997245177.USD","LU2097828714.EUR","LU2495084118.USD","LU2097828557.USD","LU0359202008.SGD","BK0183","BK1191","LU1255011170.USD","LU2543165471.USD","LU2289578879.USD","LU0359201885.HKD","BK0239","LU2148510915.USD","LU2097828631.EUR","LU1997244956.HKD","LU1820825898.SGD","BK0060","01276","BK0012","BK0196","LU1023057109.AUD","LU1997245094.SGD","LU2488822045.USD","LU1655091616.SGD","LU1781817850.SGD","LU1969619763.USD","LU2097828805.USD","LU1328615791.USD","LU1580142542.USD","LU2328871848.SGD","BK0028","600276","LU2097828474.EUR","LU2580892862.HKD","LU0405327148.USD"],"gpt_icon":0},{"id":"2583519443","title":"每日卖空追踪 | 恒瑞医药 11月13日卖空量成交69.42万股，卖空比例为10.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583519443","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583519443?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 16:30","pubTimestamp":1763022622,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间11月13日，涨1.18%，卖空量成交69.42万股，较上一交易日减少12.5%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113163258a6f6815a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113163258a6f6815a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359201612.USD","LU0359201885.HKD","LU2543165471.USD","LU1023057109.AUD","BK1191","LU0359202008.SGD"],"gpt_icon":0},{"id":"2583554823","title":"智通AH统计|11月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554823","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583554823?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 16:15","pubTimestamp":1763021705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止11月13日收盘，东北电气、中石化油服、弘业期货分列AH溢价率前三位，溢价率分别为847.37%、268.24%、266.94%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-12.28%、-0.80%、4.79%。其中山东墨龙、浙江世宝、中石化油服的偏离值位居前三，分别为36.39%、27.01%、26.60%；另外，安德利果汁、中国人寿、赣锋锂业的偏离值位居后三，分别为-23.19%、-22.80%、-18.16%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03750","06869","03143","LU0589944569.HKD","00638","LU0229945570.USD","02068","00670","01349","02866","159982","03993","01812","00300","BK1149","LU1115378108.SGD","02899","02338","01033","00874","02628","01375","00042","LU1770034418.SGD","03678","01055","03968","06031","02218","00568","IE00BMCWC346.EUR","SG9999002463.SGD","01108","LU1813983027.USD","01057","IE00BGHQDM52.EUR","LU0502904849.HKD","01138","02465","BK1594","LU1880383440.USD","00187","LU0164865239.USD","01276","02359","00895","03606","399300"],"gpt_icon":1},{"id":"2583519414","title":"医药行业收入与利润端现边际改善！创新药成为新的增长极","url":"https://stock-news.laohu8.com/highlight/detail?id=2583519414","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583519414?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 14:52","pubTimestamp":1763016731,"startTime":"0","endTime":"0","summary":"17480.2亿元的营业收入同比下降1.22%，1355.8亿元的归母净利润同比下降1.00%，这组数据既反映了传统医药业务的压力，也彰显了行业转型的决心。创新药板块的“高增长、减亏损”态势，成为医药行业亮眼的增长极。如恒瑞医药目前已在中国获批上市24款1类创新药和5款2类新药。此外，恒瑞医药在2025年第三季度宣布了多笔BD。业内表示，这种边际改善是政策效应与市场需求共振的结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113145606a6f64716&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113145606a6f64716&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU1023057109.AUD","06978","BK1191","BK1574","01276","LU0359201885.HKD","LU0359202008.SGD","02196","BK1161","LU0359201612.USD"],"gpt_icon":0},{"id":"2583051944","title":"对话恒瑞医药张连山：不止于BD，驶向“造船出海”","url":"https://stock-news.laohu8.com/highlight/detail?id=2583051944","media":"中国医药创新促...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583051944?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 14:33","pubTimestamp":1763015600,"startTime":"0","endTime":"0","summary":"出海进程亦在持续加速，已同默沙东、GSK、默克等跨国药企达成交易，超20项创新药国际临床试验正在进行，驶向“造船出海”的新目标。恒瑞的不少BD项目正是因产品符合临床需求，才能最终达成多笔出海交易。展望未来，恒瑞希望让更多新药在海外获批上市，实现“造船出海”，也让公司的产品拥有更加完整的创新价值实现路径。目前，恒瑞共有超20项创新药国际临床试验正在进行，有望继续扩大海外版图。张连山透露，恒瑞医药","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113150234a6f64ab6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113150234a6f64ab6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359201885.HKD","LU1023057109.AUD","BK1191","LU0359201612.USD","LU0359202008.SGD","LU2543165471.USD"],"gpt_icon":0},{"id":"2583592536","title":"恒瑞医药张连山：中国真正的国际性医药企业，需在15年内将本土创新产品销往全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2583592536","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583592536?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 10:49","pubTimestamp":1763002140,"startTime":"0","endTime":"0","summary":"　　11月12日-13日，上交所国际投资者大会举行。江苏恒瑞医药股份有限公司全球研发总裁张连山表示，中国真正的国际性医药企业，需在15年内将本土创新产品销往全球；而实现10-20亿美元海外创新药营收，是跻身国际一流梯队的关键一步。张连山认为，近几年，国外大公司纷纷到中国购买许可创新产品，说明国内医药公司已经具备一定实力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-13/doc-infxfnyc2682607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1023057109.AUD","LU1064131003.USD","01276","BK0188","BK0239","LU1580142542.USD","LU2488822045.USD","LU1997245094.SGD","LU1997245177.USD","BK0028","LU1781817850.SGD","LU0359201612.USD","BK0012","LU0359201885.HKD","LU0405327148.USD","LU2543165471.USD","LU2580892789.USD","LU2097828714.EUR","BK0196","LU1997244956.HKD","LU2580892862.HKD","LU2097828805.USD","LU1969619763.USD","LU0405327494.USD","LU2097828557.USD","LU1064130708.USD","LU2097828474.EUR","LU2495084118.USD","LU1328615791.USD","LU0359202008.SGD","BK0183","600276","LU2097828631.EUR","BK1191","LU2328871848.SGD","LU1255011170.USD","LU1820825898.SGD","LU2289578879.USD","LU2148510915.USD","LU1655091616.SGD","BK0060","LU1146622755.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}